Inventiva (IVA.PA) Stock Price

Inventiva Price

Euronext·CLOSED
3.70EUR-0.10 (-2.67 %)
Market closed

Over the last 12 years Inventiva grew revenue by 3.2% annually, reaching 4.48 M EUR. For Inventiva, the net margin of -7,899.6% is down versus -1,183.5% a few years ago. The consensus 12-month price target for Inventiva is 11.63 EUR, about 214.3% above where the stock trades today. Of 15 analysts, 14 rate the stock a buy — an overall Buy consensus. The stock trades about 33% above its 52-week low.

Inventiva stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Inventiva over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Inventiva stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Inventiva's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Inventiva Stock Price History
DateInventiva Price
8/3/20263.70 EUR
7/31/20263.80 EUR
7/30/20263.83 EUR
7/29/20263.93 EUR
7/28/20263.93 EUR
7/27/20263.92 EUR
7/24/20263.82 EUR
7/23/20263.81 EUR
7/22/20263.88 EUR
7/21/20263.91 EUR
7/20/20263.86 EUR
7/17/20263.92 EUR
7/16/20263.83 EUR
7/15/20263.87 EUR
7/14/20263.82 EUR
7/13/20263.71 EUR
7/10/20263.73 EUR
7/9/20263.73 EUR
7/8/20263.56 EUR
7/7/20263.33 EUR
7/6/20263.41 EUR
7/3/20263.38 EUR
7/2/20263.28 EUR
7/1/20263.17 EUR
6/30/20263.22 EUR
6/29/20263.03 EUR
6/26/20263.07 EUR
6/25/20262.97 EUR
6/24/20263.11 EUR
6/23/20263.17 EUR
6/22/20263.01 EUR
6/19/20263.00 EUR
6/18/20263.10 EUR
6/17/20263.07 EUR
6/16/20263.18 EUR
6/15/20263.37 EUR
6/12/20263.31 EUR
6/11/20263.24 EUR
6/10/20263.14 EUR
6/9/20263.26 EUR
6/8/20263.50 EUR
6/5/20263.56 EUR
6/4/20263.36 EUR
6/3/20263.28 EUR
6/2/20263.43 EUR
6/1/20264.20 EUR
5/29/20264.51 EUR
5/28/20264.57 EUR
5/27/20264.65 EUR
5/26/20264.64 EUR
5/25/20264.68 EUR
5/22/20264.49 EUR
5/21/20264.39 EUR
5/20/20264.30 EUR
5/19/20264.25 EUR
5/18/20264.40 EUR
5/15/20264.81 EUR
5/14/20264.83 EUR
5/13/20264.78 EUR
5/12/20264.91 EUR
5/11/20265.02 EUR
5/8/20264.55 EUR
5/7/20264.51 EUR
5/6/20264.55 EUR
5/5/20264.69 EUR
5/4/20264.34 EUR
4/30/20264.31 EUR
4/29/20264.20 EUR
4/28/20264.31 EUR
4/27/20264.34 EUR
4/24/20264.37 EUR
4/23/20264.50 EUR
4/22/20264.56 EUR
4/21/20264.59 EUR
4/20/20264.78 EUR
4/17/20264.82 EUR
4/16/20264.74 EUR
4/15/20264.63 EUR
4/14/20264.36 EUR
4/13/20264.41 EUR
4/10/20264.53 EUR
4/9/20264.39 EUR
4/8/20264.55 EUR
4/7/20264.55 EUR
4/2/20264.72 EUR
4/1/20264.57 EUR
3/31/20264.75 EUR
3/30/20264.80 EUR
3/27/20265.00 EUR
3/26/20265.15 EUR
3/25/20265.19 EUR
3/24/20265.20 EUR
3/23/20265.24 EUR
3/20/20265.11 EUR
3/19/20265.20 EUR
3/18/20265.13 EUR
3/17/20265.28 EUR
3/16/20265.19 EUR
3/13/20265.17 EUR
3/12/20265.32 EUR
3/11/20265.56 EUR
3/10/20265.68 EUR
3/9/20265.31 EUR
3/6/20265.19 EUR
3/5/20265.31 EUR
3/4/20265.14 EUR
3/3/20265.09 EUR
3/2/20265.31 EUR
2/27/20265.49 EUR
2/26/20265.55 EUR
2/25/20265.79 EUR
2/24/20265.72 EUR
2/23/20265.65 EUR
2/20/20265.62 EUR
2/19/20265.59 EUR
2/18/20265.37 EUR
2/17/20265.24 EUR
2/16/20265.28 EUR
2/13/20265.29 EUR
2/12/20265.25 EUR
2/11/20265.13 EUR
2/10/20265.35 EUR
2/9/20265.17 EUR
2/6/20265.02 EUR
2/5/20265.10 EUR
2/4/20265.07 EUR
2/3/20265.28 EUR
2/2/20265.14 EUR
1/30/20265.00 EUR
1/29/20265.23 EUR
1/28/20265.70 EUR
1/27/20265.74 EUR
1/26/20265.83 EUR
1/23/20265.98 EUR
1/22/20265.71 EUR
1/21/20265.52 EUR
1/20/20265.15 EUR
1/19/20265.31 EUR
1/16/20265.71 EUR
1/15/20265.28 EUR
1/14/20265.06 EUR
1/13/20264.90 EUR
1/12/20264.41 EUR
1/9/20264.09 EUR
1/8/20264.07 EUR
1/7/20264.24 EUR
1/6/20263.92 EUR
1/5/20263.94 EUR
1/2/20264.05 EUR
12/31/20253.94 EUR
12/30/20253.90 EUR
12/29/20253.91 EUR
12/24/20253.76 EUR
12/23/20253.78 EUR
12/22/20253.78 EUR
12/19/20253.65 EUR
12/18/20253.68 EUR
12/17/20253.86 EUR
12/16/20253.76 EUR
12/15/20253.72 EUR
12/12/20253.76 EUR
12/11/20253.80 EUR
12/10/20253.81 EUR
12/9/20253.64 EUR
12/8/20253.50 EUR
12/5/20253.45 EUR
12/4/20253.53 EUR
12/3/20253.48 EUR
12/2/20253.66 EUR
12/1/20253.68 EUR
11/28/20253.66 EUR
11/27/20253.75 EUR
11/26/20253.71 EUR
11/25/20253.76 EUR
11/24/20253.50 EUR
11/21/20253.46 EUR
11/20/20253.61 EUR
11/19/20253.46 EUR
11/18/20253.44 EUR
11/17/20253.53 EUR
11/14/20253.39 EUR
11/13/20253.27 EUR
11/12/20253.35 EUR
11/11/20253.26 EUR
11/10/20253.30 EUR
11/7/20253.55 EUR
11/6/20253.71 EUR
11/5/20253.60 EUR
11/4/20253.67 EUR
11/3/20253.52 EUR
10/31/20253.60 EUR
10/30/20253.41 EUR
10/29/20253.77 EUR
10/28/20253.34 EUR
10/27/20253.10 EUR
10/24/20253.04 EUR
10/23/20253.11 EUR
10/22/20253.13 EUR
10/21/20253.27 EUR
10/20/20253.33 EUR
10/17/20253.43 EUR
10/16/20253.57 EUR
10/15/20253.64 EUR
10/14/20254.00 EUR
10/13/20253.78 EUR
10/10/20253.98 EUR
10/9/20254.20 EUR
10/8/20254.51 EUR
10/7/20254.76 EUR
10/6/20255.05 EUR
10/3/20255.34 EUR
10/2/20255.20 EUR
10/1/20254.97 EUR
9/30/20254.85 EUR
9/29/20254.94 EUR
9/26/20255.05 EUR
9/25/20255.11 EUR
9/24/20254.68 EUR
9/23/20254.74 EUR
9/22/20254.67 EUR
9/19/20254.58 EUR
9/18/20254.49 EUR
9/17/20254.39 EUR
9/16/20254.41 EUR
9/15/20254.52 EUR
9/12/20254.63 EUR
9/11/20254.73 EUR
9/10/20254.71 EUR
9/9/20254.53 EUR
9/8/20254.49 EUR
9/5/20254.47 EUR
9/4/20254.47 EUR
9/3/20254.80 EUR
9/2/20254.50 EUR
9/1/20254.55 EUR
8/29/20254.89 EUR
8/28/20254.78 EUR
8/27/20254.63 EUR
8/26/20254.07 EUR
8/25/20254.03 EUR
8/22/20253.88 EUR
8/21/20253.89 EUR
8/20/20253.89 EUR
8/19/20253.80 EUR
8/18/20253.65 EUR
8/15/20253.40 EUR
8/14/20253.51 EUR
8/13/20253.20 EUR
8/12/20253.00 EUR
8/11/20252.93 EUR
8/8/20252.90 EUR
8/7/20252.87 EUR
8/6/20252.86 EUR
8/5/20252.82 EUR
8/4/20252.79 EUR
Access this data via the Eulerpool API
Get Free API Key

Inventiva Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
17.48 M EUR
-105.59 M EUR
-110.43 M EUR
Jan 1, 2024
14.72 M EUR
-97.56 M EUR
-184.21 M EUR
Jan 1, 2025
4.48 M EUR
-136.33 M EUR
-354.14 M EUR
Jan 1, 2026 (e)
6.54 M EUR
-5.95 M EUR
-42.68 M EUR
Jan 1, 2027 (e)
108.42 M EUR
-28.86 M EUR
-47.55 M EUR
Jan 1, 2028 (e)
236.84 M EUR
-236.84 M EUR
-15.32 M EUR
Jan 1, 2029 (e)
383.21 M EUR
-383.21 M EUR
-900,028.17 EUR
Jan 1, 2030 (e)
651.05 M EUR
-651.05 M EUR
40.57 M EUR

Inventiva Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 3, 2026, 5:26 PM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
4.009.006.003.006.00–4.0012.0017.0014.004.006.00108.00236.00383.00651.00
33.33125.00-33.33-50.00100.00––200.0041.67-17.65-71.4350.001,700.00118.5262.2969.97
75.0077.7883.3366.67100.00–75.00100.00100.0064.2925.0025.0025.0025.0025.0025.00
3.007.005.002.006.001.003.0012.0017.009.001.001.5027.0059.0095.75162.75
-15.00-13.00-20.00-33.00-30.00-29.00-52.00-57.00-105.00-97.00-136.00-5.00-28.00-236.00-383.00-651.00
-375.00-144.44-333.33-1,100.00-500.00–-1,300.00-475.00-617.65-692.86-3,400.00-83.33-25.93-100.00-100.00-100.00
-8.00-7.00-17.00-33.00-30.00-31.00-49.00-54.00-110.00-184.00-354.00-42.00-47.00-15.00–40.00
14.29-12.50142.8694.12-9.093.3358.0610.20103.7067.2792.39-88.1411.90-68.09––
10.0310.0316.3922.2226.7838.3239.6142.0448.6667.58186.80186.80186.80186.80186.80186.80
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Inventiva generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Inventiva retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Inventiva's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Inventiva has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Inventiva's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Inventiva stock margins

The Inventiva margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Inventiva. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Inventiva.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
75.75 %
-1,242.58 %
-1,183.50 %
Jan 1, 2022
100.00 %
-468.92 %
-445.64 %
Jan 1, 2023
100.13 %
-604.14 %
-631.84 %
Jan 1, 2024
62.47 %
-662.58 %
-1,251.10 %
Jan 1, 2025
35.07 %
-3,040.98 %
-7,899.58 %
Jan 1, 2026 (e)
35.07 %
-91.00 %
-652.45 %
Jan 1, 2027 (e)
35.07 %
-26.62 %
-43.86 %
Jan 1, 2028 (e)
35.07 %
-100.00 %
-6.47 %

Inventiva Stock Revenue, EBIT, Earnings per Share

The Inventiva earnings per share therefore indicates how much revenue Inventiva has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.11 EUR
-1.32 EUR
-1.25 EUR
Jan 1, 2022
0.29 EUR
-1.36 EUR
-1.29 EUR
Jan 1, 2023
0.36 EUR
-2.17 EUR
-2.27 EUR
Jan 1, 2024
0.22 EUR
-1.44 EUR
-2.73 EUR
Jan 1, 2025
0.02 EUR
-0.73 EUR
-1.90 EUR
Jan 1, 2026 (e)
0.11 EUR
-0.03 EUR
-0.71 EUR
Jan 1, 2027 (e)
1.81 EUR
-0.15 EUR
-0.80 EUR
Jan 1, 2028 (e)
3.96 EUR
-1.27 EUR
-0.26 EUR

Inventiva business model & stock analysis

Inventiva SA is a biopharmaceutical company based in France that specializes in the development of novel therapies for various diseases. The company was founded in 2002 by Pierre Broqua and Frédéric Cren to develop innovative drugs based on research on the human genome. Inventiva's business model is to develop a pipeline of drug candidates and either sell them or bring them into partnerships with other companies. The company has built a broad portfolio of patents and license agreements that allow it to develop a variety of products. Inventiva's research and development focuses on three key areas: fibrosis, oncology, and autoimmune diseases. In these areas, the company has several product candidates in various stages of clinical development. Inventiva's products include Lanifibranor, a drug for the treatment of fatty liver disease, which is currently in Phase III trials. Additionally, the company has several compounds in its oncology pipeline, including IVA337, IVA336, and IVA339, all of which have shown promising results in preclinical studies. In the field of autoimmune diseases, Inventiva is working on a compound called ABBV-157, which is being developed in collaboration with Abbvie. This compound is intended to help reduce inflammation in patients with rheumatoid arthritis and psoriasis. Overall, Inventiva has made significant progress in recent years and has achieved important milestones in the development of its products. The company has also entered into several partnerships with major pharmaceutical and biotech companies to bring its products to market. In 2020, Inventiva took the next important step in its growth strategy by announcing a merger with American company AbbVie. The acquisition is expected to accelerate the development and commercialization of Inventiva's products and provide the company with a strong partner in the international market. However, Inventiva has not limited itself to drug development. The company has also developed a range of services to support other companies in the development of new drugs. These include laboratory services, protein purification and analysis, cell culture, and more, offered through their own contract research organization (CRO) unit. In summary, Inventiva is an emerging company with a strong portfolio of products and services. The company has done excellent work in developing new medical technologies in recent years and is likely to have even more success in the future with the acquisition by AbbVie.

Inventiva SWOT Analysis

Strengths

Inventiva SA possesses several key strengths that contribute to its competitiveness in the market:

  • Strong and experienced management team with a successful track record.
  • Robust portfolio of intellectual property rights and patents.
  • Solid financial position and stable revenue streams.
  • Strategic partnerships with leading industry players.
  • Excellent R&D capabilities and innovative product pipeline.

Despite its strengths, Inventiva SA also faces certain weaknesses that may hamper its performance:

  • Limited market presence and brand recognition compared to larger competitors.
  • Reliance on a relatively small customer base, which increases vulnerability to economic fluctuations.
  • Overdependence on a specific technology or product line.

Inventiva SA can leverage the following opportunities to further grow and expand its business:

  • Emerging markets offer untapped potential for market penetration and increased sales.
  • Growing demand for innovative solutions in the target industry.
  • Strategic alliances and collaborations to access new markets and expand product offerings.
  • Advancements in technology that align with Inventiva SA's expertise and capabilities.

Inventiva SA faces several external threats that impede its growth and profitability:

  • Intense competition from established players with greater resources and market presence.
  • Economic downturns or fluctuations affecting consumer purchasing power.
  • Regulatory and legal challenges in intellectual property protection.
  • Disruptive technologies that may render current products or services obsolete.

Weaknesses

Despite its strengths, Inventiva SA also faces certain weaknesses that may hamper its performance:

  • Limited market presence and brand recognition compared to larger competitors.
  • Reliance on a relatively small customer base, which increases vulnerability to economic fluctuations.
  • Overdependence on a specific technology or product line.

Inventiva SA can leverage the following opportunities to further grow and expand its business:

  • Emerging markets offer untapped potential for market penetration and increased sales.
  • Growing demand for innovative solutions in the target industry.
  • Strategic alliances and collaborations to access new markets and expand product offerings.
  • Advancements in technology that align with Inventiva SA's expertise and capabilities.

Inventiva SA faces several external threats that impede its growth and profitability:

  • Intense competition from established players with greater resources and market presence.
  • Economic downturns or fluctuations affecting consumer purchasing power.
  • Regulatory and legal challenges in intellectual property protection.
  • Disruptive technologies that may render current products or services obsolete.

Opportunities

Inventiva SA can leverage the following opportunities to further grow and expand its business:

  • Emerging markets offer untapped potential for market penetration and increased sales.
  • Growing demand for innovative solutions in the target industry.
  • Strategic alliances and collaborations to access new markets and expand product offerings.
  • Advancements in technology that align with Inventiva SA's expertise and capabilities.

Inventiva SA faces several external threats that impede its growth and profitability:

  • Intense competition from established players with greater resources and market presence.
  • Economic downturns or fluctuations affecting consumer purchasing power.
  • Regulatory and legal challenges in intellectual property protection.
  • Disruptive technologies that may render current products or services obsolete.

Threats

Inventiva SA faces several external threats that impede its growth and profitability:

  • Intense competition from established players with greater resources and market presence.
  • Economic downturns or fluctuations affecting consumer purchasing power.
  • Regulatory and legal challenges in intellectual property protection.
  • Disruptive technologies that may render current products or services obsolete.

Inventiva Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Inventiva historical P/E ratio, EBIT multiple, and P/S ratio

Inventiva annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Inventiva shares outstanding

The number of shares of Inventiva was 186.8 M in 2025. This indicates how many shares Inventiva is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
39.61 M Stocks
Jan 1, 2022
42.04 M Stocks
Jan 1, 2023
48.66 M Stocks
Jan 1, 2024
67.58 M Stocks
Jan 1, 2025
186.80 M Stocks
Jan 1, 2026 (e)
186.80 M Stocks
Jan 1, 2027 (e)
186.80 M Stocks
Jan 1, 2028 (e)
186.80 M Stocks

Current Inventiva forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
93.33 % (14)
Hold
6.67 % (1)
Sell
0.00 % (0)
12M Price Target
11.63
Last Price
3.80
Currency
EUR
12M Return Potential
206.00 %
LTM Return
0 %

Inventiva Analyst Rating Actions

DateFirmActionRatingReliability
9/20/2023
Roth MKM
Roth MKM
MaintainedBuy–
8/31/2023
Guggenheim
Guggenheim
MaintainedBuy30
7/27/2023
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
6/15/2023
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/31/2023
Roth MKM
Roth MKM
MaintainedBuy–
5/25/2023
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
3/30/2023
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
3/17/2023
Stifel
Stifel
MaintainedBuy–
9/22/2022
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
11/22/2021
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Inventiva Earnings Calls

Inventiva Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
3/27/2024-0.79EUR-0.00EUR-2023 Q4

Inventiva shareholder structure

% Name
24.78276%
The Invus Group, LLC
The Invus Group, LLC
16.92663%
Eventide Asset Management, LLC
Eventide Asset Management, LLC
14.43348%
Samsara BioCapital, LLC
Samsara BioCapital, LLC
13.96941%
New Enterprise Associates (NEA)
New Enterprise Associates (NEA)
13.14759%
BVF Partners L.P.
BVF Partners L.P.
12.39138%
Great Point Partners, LLC
Great Point Partners, LLC

Inventiva Beneficial Ownership Filings (SEC 13D/G)

Free Float
55.3%
Float Shares
-
Shares Outstanding
-

Inventiva Executives and Management Board

14 members · avg. age 56 · 43 % women

Management

AO

Mr. Andrew Obenshain (50)

Chief Executive Officer, Director · since 2025

–
JV

Mr. Jean Volatier (59)

Chief Financial Officer · since 2022

–
JC

Dr. Jason Campagna (55)

President - Research and Development, Chief Medical Officer

–
AR

Ms. Alice Roudot-Ketelers (53)

Chief Operating Officer

–
PC

Ms. Pascaline Clerc (44)

Executive Vice President - Strategy and Corporate Affairs

–
ED

Mr. Eric Duranson (50)

General Counsel

–

Board of Directors

AS

Dr. Annick Schwebig (73)

Independent Director

61,200.00 EUR
HM

Mr. Heinz Maeusli (62)

Independent Director

49,200.00 EUR
MZ

Ms. Martine Zimmerman (55)

Independent Director

21,600.00 EUR
MP

Dr. Mark Pruzanski (57)

Chairman of the Board

–
NH

Ms. Nathalie Harroy (57)

Director - Human Resources

–
RA

Ms. Renee Aguiar-lucander

Independent Director

–

Inventiva Supply Chain

Inventiva Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#NameTrend
1
AbbVie
Supplier·Customer·Biotechnology·US
-0.22
0.41
-0.29
-0.85
-0.72
-0.27

Frequently asked questions about Inventiva

The business model of Inventiva SA focuses on the development and commercialization of innovative therapies for the treatment of various diseases. As a biopharmaceutical company, Inventiva SA aims to discover and develop small molecule drugs that target various nuclear receptors involved in the regulation of gene expression. By leveraging its expertise in nuclear receptors, Inventiva SA aims to bring novel therapies to market that can address unmet medical needs. With a strong pipeline of drug candidates in various stages of development, Inventiva SA is dedicated to improving patients' lives and creating value for its shareholders through the research and development of innovative therapies.

Inventiva SA is primarily active in the biopharmaceutical industry.

The main competitors of Inventiva SA in the market include other companies operating in the biopharmaceutical industry, such as Novartis, Amgen, Gilead Sciences, and Pfizer. These companies also focus on research, development, and commercialization of innovative therapies for various diseases.

Inventiva SA is a pharmaceutical company founded in 2011 in France. The company specializes in the development and commercialization of innovative therapies for the treatment of diseases with high unmet medical needs. With a strong expertise in drug discovery and medicinal chemistry, Inventiva aims to address significant therapeutic challenges through its proprietary technology platforms. The company has a diverse portfolio of drug candidates targeting a range of conditions, including fibrosis, oncology, and rare genetic diseases. Inventiva has established collaborations with various research and academic institutions to support its research efforts. With a dedicated team and promising pipeline, Inventiva SA is poised to make a significant contribution to the healthcare industry.

Inventiva SA, a leading company in the stock market, has accomplished several significant milestones. One of its notable achievements includes the successful completion of Phase 2b clinical trials for its drug candidate, lanifibranor. Additionally, Inventiva SA has successfully secured partnerships and collaborations with various pharmaceutical companies to further advance its innovative research and development. The company's commitment to building a strong and diverse portfolio has also resulted in obtaining key patents and regulatory approvals for its ground-breaking therapies. These remarkable achievements highlight Inventiva SA's dedication to revolutionizing the healthcare industry and position the company as a promising investment opportunity.

Inventiva SA is primarily present in France and Switzerland.

Inventiva SA represents values of innovation, research, and commitment to improving patients' lives. With a strong corporate philosophy, the company focuses on developing breakthrough therapies for the treatment of fibrotic diseases, oncology, and NASH. Inventiva SA's dedication to scientific excellence and collaborative partnerships drives its mission to address unmet medical needs and provide effective therapeutic solutions. Through its innovative approach and commitment to patient health, Inventiva SA has positioned itself as a leading player in the pharmaceutical industry.

Analysts currently set an average price target of 13.57 EUR for the Inventiva stock (median: 11.63 EUR), implying +257.1 % versus the latest price. The consensus is based on 15 analyst ratings.

Inventiva Analyst Price Targets 2026

15 analysts currently rate the Inventiva stock: 14 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Inventiva to generate revenue of 6.54 M EUR and earnings per share of -0.23 EUR.

Inventiva Analyst Price Targets 2026

The Inventiva share (IVA.PA) is listed on 8 stock exchanges, including: Frankfurt (6IV.F), München (6IV.MU), Düsseldorf (6IV.DU), London (0RNK.L), London (0RNK.L), Paris (IVA.PA).

The company Inventiva SA is a company specializing in the development of therapies for serious diseases. The company is based in France and also has branches in Germany and the USA. The various divisions of Inventiva SA include drug development and clinical research, as well as the manufacturing of diagnostics and medications. The company specializes in the development of medications for serious diseases such as rare genetic disorders or fibrosis. It takes an interdisciplinary approach and works closely with research institutions and biopharmaceutical companies. One of Inventiva SA's key products is the medication Lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH). NASH is a liver disease caused by obesity and diabetes, which can lead to cirrhosis and liver cancer. Lanifibranor is intended to improve liver health and reduce inflammation by influencing various signaling pathways in the body. The medication is currently in clinical development and has already shown promising results in clinical trials. Another product of Inventiva SA is the diagnostic test called Odiparcil, which supports the treatment of mucopolysaccharidosis (MPS). MPS is a rare genetic disease that can cause debilitating symptoms such as bone pain, shortness of breath, and changes in facial features. The Odiparcil test allows for the diagnosis of MPS and helps doctors choose the right therapy for their patients. Inventiva SA mainly finances its research and development projects through partnerships and licensing agreements with major pharmaceutical companies. For example, the company has a partnership with AbbVie, a global leader in biopharmaceuticals, to advance the development of Lanifibranor. Additionally, the company has significant investments from public and private investors as well as foundations. Overall, Inventiva SA takes a strategic and scientific approach to develop medications and diagnostics for serious diseases with unmet medical needs. The company has a strong pipeline of products in development and a promising partnership with a global biopharmaceutical manufacturer. With its focus on developing innovative therapies for complex diseases, Inventiva SA can contribute to improving the lives of millions of patients worldwide.

The expected revenue of Inventiva is 6.54 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Inventiva is -42.68 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Inventiva is currently -16.19. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Inventiva stock.

The price-to-sales ratio (P/S) of Inventiva is currently 105.65. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Inventiva stock.

The Eulerpool Quality Score for Inventiva is 2/10.

The ISIN of Inventiva is FR0013233012. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Inventiva is A2DLV9. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Inventiva is IVA.PA. The ticker symbol is used to trade Inventiva shares on the stock exchange.

Inventiva paid dividends every year for the past 0 years.

Inventiva is assigned to the 'Health' sector.

The dividends of Inventiva are distributed in EUR.

All fundamentals and in-depth analysis of Inventiva

Our stock analysis for Inventiva stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inventiva. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Inventiva Stock
Inventiva Revenue→
Inventiva Stock
Inventiva Net Income→
Inventiva Stock
Inventiva P/E→
Inventiva Stock
Inventiva P/S→
Inventiva Stock
Inventiva EBIT→
Inventiva Stock
Inventiva Dividend→
Inventiva Stock
Inventiva Directors Dealings→
Inventiva Stock
Inventiva Stocks→
Inventiva Stock
Inventiva Market capitalization→
Inventiva Stock
Inventiva Debt→
Inventiva Stock
Inventiva Liabilities→
Inventiva Stock
Inventiva Equity→
Inventiva Stock
Inventiva AAQS→
Inventiva Stock
Inventiva Employees→
Inventiva Stock
Inventiva ROE→
Inventiva Stock
Inventiva ROA→
Inventiva Stock
Inventiva ROCE→
Inventiva Stock
Inventiva News→
Inventiva Stock
Inventiva Analyst Price Targets→

Health Stocks

Inventiva SaInventisBio CoInventurus Knowledge SolutionsInventionmedInvex TherapeuticsInventage LabInvionInvent Medic SwedenInvivydInvech HoldingsINVO FertilityIntuitive SurgicalAll Stocks A–Z →